JNJ – Johnson & Johnson
Johnson & JohnsonJNJ
$159.82Name : Johnson & Johnson
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $385,142,259,712.00
EPSttm : 5.79
Johnson & Johnson
$159.82
2.87%$4.46Float Short %
1.03
Margin Of Safety %
20
Put/Call OI Ratio
0.57
EPS Next Q Diff
0.68
EPS Last/This Y
4.74
EPS This/Next Y
0.54
Price
159.82
Target Price
169.61
Analyst Recom
2.29
Performance Q
10.51
Relative Volume
1.4
Beta
0.4
Ticker: JNJ
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | JNJ | 165.06 | 0.60 | 0.59 | 447909 |
| 2025-03-06 | JNJ | 165.82 | 0.60 | 0.60 | 464748 |
| 2025-03-07 | JNJ | 166.69 | 0.60 | 0.34 | 471664 |
| 2025-03-10 | JNJ | 168.42 | 0.59 | 0.49 | 468709 |
| 2025-03-11 | JNJ | 165.69 | 0.60 | 0.60 | 475314 |
| 2025-03-12 | JNJ | 162.87 | 0.60 | 0.78 | 477406 |
| 2025-03-13 | JNJ | 162.97 | 0.60 | 0.79 | 483670 |
| 2025-03-14 | JNJ | 162.35 | 0.60 | 2.35 | 488298 |
| 2025-03-17 | JNJ | 162.86 | 0.62 | 0.72 | 464836 |
| 2025-03-18 | JNJ | 164.35 | 0.62 | 0.40 | 470796 |
| 2025-03-19 | JNJ | 162.96 | 0.62 | 0.38 | 484289 |
| 2025-03-20 | JNJ | 163.01 | 0.62 | 0.35 | 492744 |
| 2025-03-21 | JNJ | 163.54 | 0.61 | 0.46 | 497237 |
| 2025-03-24 | JNJ | 163.24 | 0.53 | 0.30 | 383046 |
| 2025-03-25 | JNJ | 161.48 | 0.52 | 0.59 | 394120 |
| 2025-03-26 | JNJ | 161.67 | 0.52 | 0.74 | 405918 |
| 2025-03-27 | JNJ | 163.11 | 0.53 | 1.09 | 414620 |
| 2025-03-28 | JNJ | 163.69 | 0.55 | 0.73 | 425030 |
| 2025-03-31 | JNJ | 165.8 | 0.54 | 0.61 | 410890 |
| 2025-04-01 | JNJ | 153.24 | 0.52 | 0.99 | 432062 |
| 2025-04-02 | JNJ | 155.34 | 0.57 | 0.64 | 455513 |
| 2025-04-03 | JNJ | 159.81 | 0.57 | 0.37 | 470859 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | JNJ | 165.14 | -2.6 | 11779.3 | 10.57 |
| 2025-03-06 | JNJ | 165.86 | -2.6 | 11954.7 | 10.57 |
| 2025-03-07 | JNJ | 166.68 | -2.6 | 11973.0 | 10.57 |
| 2025-03-10 | JNJ | 167.69 | -2.6 | 11997.9 | 10.57 |
| 2025-03-11 | JNJ | 165.84 | -2.6 | 11512.3 | 10.57 |
| 2025-03-12 | JNJ | 162.84 | -2.6 | 11310.3 | 10.57 |
| 2025-03-13 | JNJ | 162.99 | -2.6 | 11477.9 | 10.57 |
| 2025-03-14 | JNJ | 162.81 | -2.6 | 11796.1 | 10.57 |
| 2025-03-17 | JNJ | 162.84 | -2.7 | 11832.6 | 10.57 |
| 2025-03-18 | JNJ | 164.32 | -2.7 | 12085.6 | 10.57 |
| 2025-03-19 | JNJ | 162.99 | -2.7 | 11609.6 | 10.57 |
| 2025-03-20 | JNJ | 163.02 | -2.7 | 11832.7 | 10.57 |
| 2025-03-21 | JNJ | 163.62 | -2.7 | 11931.9 | 10.57 |
| 2025-03-24 | JNJ | 163.29 | -2.7 | 11768.4 | 10.57 |
| 2025-03-25 | JNJ | 161.02 | -2.7 | 11432.7 | 10.57 |
| 2025-03-26 | JNJ | 161.72 | -2.7 | 11950.8 | 10.57 |
| 2025-03-27 | JNJ | 163.08 | -2.7 | 12066.2 | 10.57 |
| 2025-03-28 | JNJ | 163.71 | -2.7 | 11928.4 | 10.57 |
| 2025-03-31 | JNJ | 165.84 | -2.7 | 12196.9 | 10.57 |
| 2025-04-01 | JNJ | 153.25 | -2.7 | 9670.9 | 10.57 |
| 2025-04-02 | JNJ | 155.36 | -2.7 | 12217.6 | 10.58 |
| 2025-04-03 | JNJ | 159.82 | -2.7 | 12641.3 | 10.58 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | JNJ | -0.62 | 0.48 | 0.76 |
| 2025-03-06 | JNJ | -0.62 | 0.48 | 0.76 |
| 2025-03-07 | JNJ | -0.62 | 0.48 | 0.76 |
| 2025-03-10 | JNJ | -0.62 | 0.71 | 0.76 |
| 2025-03-11 | JNJ | -0.62 | 0.71 | 0.76 |
| 2025-03-12 | JNJ | -0.62 | 0.71 | 0.96 |
| 2025-03-13 | JNJ | -0.62 | 0.71 | 0.96 |
| 2025-03-14 | JNJ | -0.62 | 0.71 | 0.96 |
| 2025-03-17 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-18 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-19 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-20 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-21 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-24 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-25 | JNJ | -0.62 | 0.72 | 0.96 |
| 2025-03-26 | JNJ | -0.62 | 0.72 | 1.03 |
| 2025-03-27 | JNJ | -0.62 | 0.72 | 1.03 |
| 2025-03-28 | JNJ | -0.62 | 0.72 | 1.03 |
| 2025-03-31 | JNJ | -0.62 | 0.72 | 1.03 |
| 2025-04-01 | JNJ | -0.62 | 0.72 | 1.03 |
| 2025-04-02 | JNJ | -0.62 | 0.72 | 1.03 |
| 2025-04-03 | JNJ | -0.62 | 0.72 | 1.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.04
Avg. EPS Est. Current Quarter
2.64
Avg. EPS Est. Next Quarter
2.72
Insider Transactions
-0.62
Institutional Transactions
0.72
Beta
0.4
Average Sales Estimate Current Quarter
21646
Average Sales Estimate Next Quarter
22444
Fair Value
192.31
Quality Score
95
Growth Score
73
Sentiment Score
73
Actual DrawDown %
14.4
Max Drawdown 5-Year %
-18.4
Target Price
169.61
P/E
27.57
Forward P/E
14.48
PEG
5.43
P/S
4.34
P/B
5.38
P/Free Cash Flow
19.41
EPS
5.8
Average EPS Est. Cur. Y
10.58
EPS Next Y. (Est.)
11.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
15.84
Relative Volume
1.4
Return on Equity vs Sector %
-0.1
Return on Equity vs Industry %
-7.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
12641.3
Johnson & JohnsonSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 138100
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
stock quote shares JNJ – Johnson & Johnson Stock Price stock today
news today JNJ – Johnson & Johnson stock forecast ,stock prediction 2023 2024 2025
marketwatch JNJ – Johnson & Johnson yahoo finance google finance
stock history JNJ – Johnson & Johnson invest stock market
stock prices JNJ premarket after hours
ticker JNJ fair value insiders trading